Literature DB >> 21729946

Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study.

Ting Wang1, Yong Duan.   

Abstract

Antibody single-chain variable fragments (scFvs) offer particular advantages over the full-size antibodies, including easy expression, efficient local concentration and fast body clearance. However, scFvs typically show low thermal stability that limits their biomedical and biotechnological applications. In this study, we examined the thermal stability of the human and murine vascular endothelial growth factor antibody scFv fragment by molecular dynamics simulations. A consistent observation was the dissociation of the light-chain (VL) and heavy-chain (VH) domains and loss of the native structures of both domains in the simulations at the elevated temperatures. The stability-limiting structural elements in the protein were revealed from the detailed analyses on the native contacts. We found that dissociation of the VL-VH domains was the first event leading to the unfolding of the native structure of the protein and the disruption of the VL-VH interface was largely due to the break of the interfacial hydrophobic and aromatic interactions while the hydrogen-bonding interaction between Gln38 in VL and Gln39 in VH remained. Within the β-barrel structure of the VL and VH domains, β-strands β6, β2 and β11 appeared to be the least stable. In addition, we found that the VH domain was more thermally resistant than the VL domain. Based on these findings, we discussed potential strategies to improve the stability of this therapeutically important scFv fragment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729946      PMCID: PMC3160207          DOI: 10.1093/protein/gzr029

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  32 in total

Review 1.  Stability engineering of antibody single-chain Fv fragments.

Authors:  A Wörn; A Plückthun
Journal:  J Mol Biol       Date:  2001-02-02       Impact factor: 5.469

2.  A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations.

Authors:  Yong Duan; Chun Wu; Shibasish Chowdhury; Mathew C Lee; Guoming Xiong; Wei Zhang; Rong Yang; Piotr Cieplak; Ray Luo; Taisung Lee; James Caldwell; Junmei Wang; Peter Kollman
Journal:  J Comput Chem       Date:  2003-12       Impact factor: 3.376

Review 3.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.

Authors:  Stefan Ewert; Annemarie Honegger; Andreas Plückthun
Journal:  Methods       Date:  2004-10       Impact factor: 3.608

4.  Engineering an ultra-stable affinity reagent based on Top7.

Authors:  Curt B Boschek; David O Apiyo; Thereza A Soares; Heather E Engelmann; Noah B Pefaur; Tjerk P Straatsma; Cheryl L Baird
Journal:  Protein Eng Des Sel       Date:  2009-03-25       Impact factor: 1.650

5.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Authors:  H P Gerber; J Kowalski; D Sherman; D A Eberhard; N Ferrara
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

6.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

7.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Authors:  M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

8.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 9.  Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity.

Authors:  Jason Konner; Jakob Dupont
Journal:  Clin Colorectal Cancer       Date:  2004-10       Impact factor: 4.481

10.  Molecular dynamics simulations of the unfolding of beta(2)-microglobulin and its variants.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  Protein Eng       Date:  2003-08
View more
  10 in total

Review 1.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

2.  Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Authors:  Kathy Zhang; Melissa L Geddie; Neeraj Kohli; Tad Kornaga; Dmitri B Kirpotin; Yang Jiao; Rachel Rennard; Daryl C Drummond; Ulrik B Nielsen; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  Directed evolution of a fluorogen-activating single chain antibody for function and enhanced brightness in the cytoplasm.

Authors:  Bradley P Yates; Michelle A Peck; Peter B Berget
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 4.  Strategies to Address Chimeric Antigen Receptor Tonic Signaling.

Authors:  Adam Ajina; John Maher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.261

Review 5.  Computer-aided antibody design.

Authors:  Daisuke Kuroda; Hiroki Shirai; Matthew P Jacobson; Haruki Nakamura
Journal:  Protein Eng Des Sel       Date:  2012-06-02       Impact factor: 1.650

6.  Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.

Authors:  Young Pil Kim; Dongsun Park; Jae Jin Kim; Won-Jae Chi; Won-Jae Choi; Sun Hee Lee; Seo Yun Lee; Soyeon Kim; Jee Min Chung; Jinseon Jeon; Byoung Dae Lee; Joo-Ho Shin; Yun-Il Lee; Hyeseong Cho; Jeong-Min Lee; Ho Chul Kang
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 7.  Nanoyeast and Other Cell Envelope Compositions for Protein Studies and Biosensor Applications.

Authors:  Yadveer S Grewal; Muhammad J A Shiddiky; Stephen M Mahler; Gerard A Cangelosi; Matt Trau
Journal:  ACS Appl Mater Interfaces       Date:  2016-11-04       Impact factor: 9.229

8.  Determinants of the assembly and function of antibody variable domains.

Authors:  Eva Maria Herold; Christine John; Benedikt Weber; Stephan Kremser; Jonathan Eras; Carolin Berner; Sabrina Deubler; Martin Zacharias; Johannes Buchner
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

9.  Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2.

Authors:  Mahiuddin Ahmed; Jian Hu; Nai-Kong V Cheung
Journal:  Front Immunol       Date:  2014-08-14       Impact factor: 7.561

10.  Comparison of the pH- and thermally-induced fluctuations of a therapeutic antibody Fab fragment by molecular dynamics simulation.

Authors:  Cheng Zhang; Nuria Codina; Jiazhi Tang; Haoran Yu; Nesrine Chakroun; Frank Kozielski; Paul A Dalby
Journal:  Comput Struct Biotechnol J       Date:  2021-05-04       Impact factor: 7.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.